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Abstract
Background: Esophageal adenocarcinoma (EAC) is a rarely curable disease and is rapidly rising worldwide in incidence.
Barret’s esophagus (BE) and high-grade dysplasia (HGD) are considered major risk factors for invasive adenocarcinoma. In
the current study, unbiased global metabolic profiling methods were applied to serum samples from patients with EAC, BE
and HGD, and healthy individuals, in order to identify metabolite based biomarkers associated with the early stages of EAC
with the goal of improving prognostication.
Methodology/Principal Findings: Serum metabolite profiles from patients with EAC (n=67), BE (n=3), HGD (n=9) and
healthy volunteers (n=34) were obtained using high performance liquid chromatography-mass spectrometry (LC-MS)
methods. Twelve metabolites differed significantly (p,0.05) between EAC patients and healthy controls. A partial least-
squares discriminant analysis (PLS-DA) model had good accuracy with the area under the receiver operative characteristic
curve (AUROC) of 0.82. However, when the results of LC-MS were combined with 8 metabolites detected by nuclear
magnetic resonance (NMR) in a previous study, the combination of NMR and MS detected metabolites provided a much
superior performance, with AUROC=0.95. Further, mean values of 12 of these metabolites varied consistently from healthy
controls to the high-risk individuals (BE and HGD patients) and EAC subjects. Altered metabolic pathways including a
number of amino acid pathways and energy metabolism were identified based on altered levels of numerous metabolites.
Conclusions/Significance: Metabolic profiles derived from the combination of LC-MS and NMR methods readily distinguish
EAC patients and potentially promise important routes to understanding the carcinogenesis and detecting the cancer.
Differences in the metabolic profiles between high-risk individuals and the EAC indicate the possibility of identifying the
patients at risk much earlier to the development of the cancer.
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Introduction
Esophageal cancer is a deadly disease with an estimated 16,640
new cases and 14,500 deaths in the United States in 2010 [1]. In the
year 2000 the corresponding numbers were 12,300 and 12,100,
respectively [2], which indicatea significant rise in incidence. Of the
twocancertypes,esophagealadenocarcinoma(EAC)andsquamous
cell carcinoma, EAC is more prevalent in the United States.
Although the risk factors associated with the EAC are not clearly
understood to date, Barrett’s esophagus (BE) is considered to be a
factor for the carcinogenesis of the esophagus [3]. In addition, high-
grade dysplasia (HGD) is considered as an immediate precursor to
invasive adenocarcinoma [4]. However, no intervention currently
exists that can prevent the progression of BE or HGD to EAC [5].
The traditional methods for diagnosing esophageal cancer,
including endoscopy and barium swallow, suffer from poor
specificity and sensitivity, which typically result in detection of the
disease only at an advanced stage [6,7,8,9].Alternatively,it is hoped
that a certain subset of molecular biomarkers can characterize the
stage of the disease and help personalize treatment [10]. At the
molecular level, carcinogenesis of esophagus is thought to be a
complex process involving multiple genetic abnormalities and
environmental factors. Numerous studies report specific alterations
in proteins, genes and metabolic pathways in EAC that may be
useful to aid in the diagnosis, prognosis and treatment of esophageal
cancer [11,12,13,14]. Microarray studies have also focused
discovery of new markers based on individual tumor genetic
composition [15]. However, reliable markers, especially at an early
and potentially curative stage, are still in great demand.
Metabolomics, also commonly known as metabolic profiling and
metabonomics, is a fast growing field in systems biology and offers a
powerful and promising approach to identify biomarkers associated
with cancer and other diseases. Metabolomics focuses on deriving
the concentrations and fluxes of low molecular weight metabolites
(,,1 kDa) in biofluids or tissue, which provide detailed informa-
tion on biological systems and their current status [16,17]. Mass
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spectroscopy are the two most powerful and commonly used
analytical methods for metabolic fingerprinting [17,18]. The two
methods are complementary; while MS is highly sensitive, NMR is
highly quantitative and reproducible. Utilization of both MS and
NMR methods leads to the routine analysis of over 1000
metabolites.
A growing number of metabolomics studies have been reported
for detecting various cancers [19,20,21,22,23]. However, studies
that focus on EAC are still relatively small in number. Recently,
two papers reported on the analysis of tissue metabolites using
magic-angle spinning (MAS) NMR and gas chromatography (GC)
MS each combined with multivariate statistical methods [24,25].
Both works reported a number of statistically significant
distinguishing metabolites. Another
1H NMR study investigated
human plasma and identified variations in several metabolite
concentrations associated with EAC that differed among ethnic
groups [26]. Efforts in our laboratory have been focused on the
development of metabolomics tools and biomarker candidates to
detect early EAC and to identify patients at high risk of developing
EAC. We recently reported metabolomics-based investigations of
EAC using
1H NMR spectroscopy and showed that eight serum
metabolites differentiated EAC from healthy controls [27]. We
also targeted a number of nucleosides in serum using liquid
chromatography-triple quadruple (LC-QqQ) MS and showed very
significant variations in a number of normal and methylated
nucleosides in EAC [28]. With the goal of enhancing the sensitivity
and specificity of the patient classification as well as identifying
individuals at risk of developing the cancer, in this study we
applied global metabolic profiling approach to the serum samples
from EAC, BE and HGD patients, and healthy controls using
highly sensitive and resolved time-of-flight mass spectrometry
coupled with liquid chromatography (LC-TOF) MS. Metabolic
profiles were analyzed separately and in combination with
previously derived metabolite markers using NMR methods
[27]. We evaluated the combination of NMR and MS data in
terms of their performance in classifying EAC patients and healthy
controls when compared to the performance of either MS or
NMR data alone. The ability of the metabolic profiles to
distinguish high-risk individuals (BE and HGD patients) from
EAC as well as healthy controls was examined. We also identified
a number of metabolites that acted as trending markers, in that
their mean levels increased/decreased continuously from healthy
controls to high-risk subjects and then EAC patients.
Materials and Methods
Chemicals
Deuterium oxide (99.9% D) was purchased from Cambridge
Isotope Laboratories, Inc. (Andover, MA). Trimethylsilylpropionic
acid-d4 sodium salt (TSP), tridecanoic acid, chlorophenylalanine,
lactic acid, valine, leucine, isoleucine, methionine, carnitine,
tyrosine, tryptophan, myristic acid, margaric acid, linolenic acid,
linoleic acid and pyroglutamic acid were purchased from Sigma-
Aldrich (analytical grade, St. Louis, MO). 5-hydroxytryptophan
was purchased from Alfa-Aesar (analytical grade, Ward Hill, MA).
HPLC-grade methanol and acetic acid were purchased from
Fisher Scientific (Pittsburgh, PA). Deionized water was obtained
from an EASYpure II UV water purification system (Barnstead
International, Dubuque, IA).
Serum sample collection and storage
Fasting blood samples from patients with histologically proven
EAC (n=67), HGD (n=9) and BE (n=3) were collected at the
Indiana University School of Medicine (Indianapolis, IN). The
detailed clinicopathologic characteristics of EAC patients were
described in our previous paper [27], and a summary is shown in
Table S1. We used 68 EAC, 11 HGD and 5 BE samples in the
previous NMR study. However, due to the limited amounts of
some samples, we removed 1 EAC, 2 HGD and 2 BE samples for
the LC-MS experiments and further analysis in this work; the
corresponding NMR data was also excluded from the combined
analysis and discussion. Blood samples from healthy volunteers
(n=34) were obtained under fasting conditions. Each blood
sample was allowed to clot for 45 min and then centrifuged at
2,000 rpm for 10 min. The serum was collected, aliquoted in a
separate vial, frozen, and shipped over dry ice to Purdue
University (West Lafayette, IN), where they were stored at
280uC until use. All samples were collected following the protocol
approved by Indiana University School of Medicine and Purdue
University Institutional Review Boards. All subjects included in the
study provided written informed consent according to institutional
guidelines.
Sample preparation and data acquisition
For LC-MS analysis, frozen serum samples were thawed, and
the protein was precipitated by mixing 100 mL serum and 200 mL
cold methanol. Two internal standards, tridecanoic acid and
chlorophenylalanine were also included to monitor the extraction
efficiency. The mixture was centrifuged at 13200 rpm for 10 min.
The supernatant solution obtained after protein removal was dried
under vacuum and the obtained residue was reconstituted in
15 mL methanol/water (1:1) solution. The resulting solution was
again centrifuged at 13200 rpm for 10 min to remove particulate
matter, if any, and the supernatant was transferred to an LC vial.
Separately, a pooled sample was obtained by mixing together
20 mL from each of 20 human serum samples randomly selected
from all the samples, and the metabolites were extracted using the
same procedure as above. This pooled sample, referred to as the
quality control (QC) matrix sample, was subjected to analysis
periodically between every 10 samples. QC sample data also
served as technical replicates throughout the data set to assess
process reproducibility. LC-MS analysis was performed using an
Agilent LC-QTOF system (Agilent Technologies, Santa Clara,
CA) consisting of an Agilent 1200 SL liquid chromatography
system coupled online with an Agilent 6520 time-of-flight mass
spectrometer. A 3 mL aliquot of reconstituted sample was injected
onto a 2.1650 mm Agilent Zorbax Extend-C18 1.8 mm particle
column with a 2.1630 mm Agilent Zorbax SB-C8 3.5 mm particle
guard column, which were both heated to 60uC. Serum
metabolites were gradient-eluted at 600 mL/min using mobile
phase A: 0.2% acetic acid in water and mobile phase B: 0.2%
acetic acid in methanol (2% to 98% B in 13 min, 98% B for
6 min). Electrospray ionization (ESI) was used in positive mode.
The MS interface capillary was maintained at 325uC, with a
sheath gas flow of 9 L/min. The spray voltage for positive ion
injection was 4.0 kV. The mass analyzer was scanned over a range
of 50–1000 m/z. Agilent MassHunter Workstation LC-TOF and
QTOF Acquisition software (B.02.01) was used for automatic peak
detection and mass spectrum deconvolution.
Detailed procedures for sample preparation and NMR
experiments were recently published elsewhere [27]. Briefly,
frozen serum samples were thawed, and 200 mL was mixed with
350 mLo fD 2O. Resulting solutions were transferred to 5-mm
NMR tubes. A 60 mL solution of TSP (0.12 mg/mL) in a sealed
capillary was utilized as an internal standard, which acted as the
chemical shift reference (d=0.00). All
1H NMR experiments were
carried out at 25uC on a Bruker DRX-500 spectrometer equipped
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1H inverse detection probe with triple axis
magnetic field gradients.
1H NMR spectra were acquired using the
standard one-dimensional CPMG (Carr-Purcell-Meiboom-Gill)
pulse sequence with water signal presaturation. Each dataset was
averaged over 64 transients using 16 K time domain points. The
data were Fourier transformed after multiplying by an exponential
window function with a line broadening of 1 Hz, and the spectra
were phase and baseline corrected using Bruker TopSpin software
(version 3.0).
Data analysis
LC-MS data was processed using Agilent’s MassHunter
Qualitative Analysis software (version B.03.01) for compound
identification. A list of ion intensities for each detected peak was
generated using a retention time (RT) index and m/z data as the
identifiers for each ion. Agilent MassHunter Workstation Mass
Profiler Professional software (version B.02.00) was then used for
compound peak alignment. A filter was set to remove any
metabolite signals that had missing peaks (ion intensity=1) in
more than 10% of the samples in any group. Peaks from internal
standards were also removed. Finally, the Agilent Formula
Database (Agilent, 2010) was used for compound identification
by matching the accurate mass spectrum to a database of
metabolite compounds. Unpaired Student’s t-test analysis of the
data was performed to assess the differences of detected compound
intensities among EAC, BE and HGD samples, and healthy
controls. Metabolites with low p-values (,0.05) were selected as
potential biomarker candidates and verified from the mass spectra
and RTs of authentic commercial compounds run separately. The
fold change (FC) for each metabolite was calculated to determine
metabolite’s variation between the groups.
NMR spectral regions were binned to 4 K buckets of equal
width (1.5 Hz) to minimize errors due to any fluctuations of
chemical shifts arising from pH or ion concentration variations.
Table 1. Differentiating metabolites (p-value ,0.05) among EAC, high-risk (BE and HGD) and control groups.
Metabolite Detection EAC vs Control EAC vs High-risk High risk vs Control
p-value
a FC
b p-value
a FC
b p-value
a FC
b
lactic acid LC-MS 1.2E-07 1.6 3.4E-02 1.6
NMR 2.7E-03 1.3 1.6E-02 1.4
valine LC-MS 2.9E-07 21.6 1.0E-02 1.6
NMR 3.7E-02 1.2
leucine/isoleucine
c LC-MS 2.7E-07 21.2 4.2E-02 1.2
methionine LC-MS 2.0E-05 21.6 2.4E-02 -1.6
carnitine LC-MS 5.7E-05 1.2
tyrosine LC-MS 4.0E-03 21.1
NMR 3.7E-02 1.2
tryptophan LC-MS 3.2E-05 21.2
5-hydroxytryptophan LC-MS 2.6E-02 21.1
myristic acid LC-MS 1.2E-03 21.4 1.8E-02 21.4
margaric acid LC-MS 9.5E-03 1.3
linolenic acid LC-MS 1.5E-02 21.4 4.3E-02 21.2
linoleic acid LC-MS 1.1E-04 21.5
pyroglutamic acid LC-MS 9.2E-06 2.0 1.4E-04 22.2
glutamine NMR 3.0E-02 1.1
b-hydroxybutyrate NMR 2.3E-05 1.3
citrate NMR 3.3E-04 1.3
unknown 1 NMR 3.0E-05 1.3
lysine NMR 9.6E-04 1.1 2.8E-02 1.2
creatinine NMR 2.2E-02 1.2
glucose NMR 1.5E-04 1.2
N-acetylated protein NMR 6.4E-04 1.2 3.7E-02 21.1
proline NMR 3.1E-03 22.7 1.3E-02 2.1
histidine NMR 7.4E-03 1.3
alanine NMR 9.2E-03 1.3
glutamate NMR 3.6E-02 1.2
unknown 2 NMR 1.4E-02 21.5
ap-value determined from Student’s t-test, only p-values ,0.05 are displayed;
bFC: fold change between esophageal adenocarcinoma (EAC) and healthy controls. Positive sign indicates a higher level in EAC and a negative value indicates a lower
level;
cThe structural isomers of leucine and isoleucine could not be separated with the current LC method.
doi:10.1371/journal.pone.0030181.t001
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1.48 ppm, and normalized using the integrated TSP signal.
Spectral regions of 0.3 to 10.0 ppm were used for the analysis after
deleting the water and urea signals (4.5 to 6.0 ppm). Univariate
analysis was performed by applying the unpaired Student’s t-test to
identify significantly different spectral bins among EAC, BE and
HGD patients, and healthy controls. Bins that showed significant
differences between various patient/controls groups were then
assigned to the corresponding metabolites by comparing chemical
shifts and multiplicities of peaks to the literature or online
databases [29,30,31]. The characteristic spectral regions for each
metabolite were integrated, and p-values and fold changes between
different groups were calculated.
The MS/NMR data of the selected statistically significant
metabolites (with p,0.05) were imported into Matlab (R2008a,
Mathworks, Natick, MA) installed with a PLS toolbox (version 4.1,
Eigenvector Research, Inc., Wenatchee, WA) for PLS-DA
analyses. The X matrix, consisting of the MS/NMR spectral
data, was autoscaled prior to all statistical analyses. Depending on
the group, each subject was assigned a ‘‘0’’ (i.e., patient) and ‘‘1,’’
(i.e., healthy control) to serve as the (one-dimensional) Y matrix.
Leave-one-out cross validation (CV) was chosen, and the number
of latent variables (LVs) was selected according to the minimum
root mean square error of CV procedure. Predictions were made
visually using a Y-predicted scatter plot with a cut-off value chosen
to minimize errors in class membership. The R statistical package
(version 2.8.0) was used to generate receiver operating character-
istics (ROC) curves, calculate and compare sensitivity, specificity
and area under the ROC curve (AUROC).
Results
The LC-MS spectrum for each serum sample consisted of more
than 5000 features of which nearly 1400 peaks were assigned to
metabolites using the Agilent database. Peaks from the spectra that
were missing in more than 10% of the samples from any group were
omitted from further analysis. The use of this filter and the Agilent
chemical library resulted in a total of approximately 200 indentified
metabolites most common to all the groups. Further, to identify
specific metabolites that best correlated with the differences in
biological status for the various comparisons, the library-identified
metabolites were analyzed using univariate analysis. The results
showed that 40 metabolites varied significantly (p,0.05) between
either EAC and healthy controls, EAC and high-risk patients (BE
and HGD patients), or high-risk patients and healthy controls.
Thirteen of these metabolites could be verified from the mass
spectra and retention times of the authentic commercial com-
pounds. Table S2 shows the list of the verified metabolites from LC-
MS along with their formulae, masses and retention times.
Similarly, as shown in Table S3, fifteen patient-class differentiating
metabolites with low p-values (p,0.05) obtained by integrating the
relevant NMR peaks were confirmed by matching the observed
chemical shifts and multiplicities with the previously reported data
[29,30,31].
The summary of the metabolite biomarker candidates from LC-
MS and NMR with their p-values and fold changes are shown in
Table 1. ANOVA was also performed, with results that closely
paralleled those from the t-test (Table S4). However, since we were
interested in identifying individual markers that distinguished each
of the three patient cohorts separately, we used the t-test data to
identify markers for model building. The sensitivity, specificity and
AUROC values from the PLS-DA models of each comparison are
listedinTable 2.Comparison ofMS and NMRdata usingthet-test,
separately, showed no significant differences due to gender, age or
cancer stage (p.0.05) between EAC and controls (Table S5).
Comparing metabolic profiles between EAC patients and
healthy controls
As shown in Table 1, twelve metabolite marker candidates
detected by LC-MS differentiated EAC patients and healthy
controls, and their identities were confirmed with authentic
compounds. Figure S1 shows the box-and-whisker plots for the
peak intensities of the 12 differentiating biomarker candidates. As
seen in Table 1 and Figure S1, the levels of lactic acid, carnitine
and margaric acid were higher, and those of valine, leucine/
isoleucine (these structural isomers could not be separated with the
current LC method), methionine, tyrosine, tryptophan, 5-hydro-
xytryptophan, myristic acid, linolenic acid and linoleic acid were
lower in EAC patients compared to healthy controls.
The marker candidates from
1H NMR analysis have been
reported in our previous study [27]. Briefly, a set of 8 metabolites,
Table 2. Comparison of sensitivity, specificity and AUROC values from different PLS-DA models using differentiating metabolites
detected individually by NMR or MS and their combination.
Comparison Number of candidate markers Sensitivity Specificity AUROC
MS NMR
EAC vs Control 12 - 77% 86% 0.82
- 8 82% 88% 0.86
12 8 91% 91% 0.95
8
a 4
a 89% 90% 0.92
EAC vs High-risk 7 - 83% 80% 0.87
- 8 77% 77% 0.72
7 8 67% 97% 0.82
8
a 4
a 75% 70% 0.78
High-risk vs Control 1 - 74% 75% 0.76
- 4 68% 92% 0.80
1 4 65% 92% 0.80
aTrending markers that progressively change in their levels between EAC, high risk (BE and HGD) and healthy controls (see Figure 3).
doi:10.1371/journal.pone.0030181.t002
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lactate, glucose and an unknown molecule were statistically
significant (p,0.05), and higher levels of each of those metabolites
in the EAC specimens were observed (Table 1).
Figure 1 shows the comparison of performance of 3 metabolic
profiles between EAC patients and healthy controls. A PLS-DA
model using the twelve LC-MS derived metabolites (and leave-one-
out cross valuation) provided 77% sensitivity and 86% specificity
with an AUROC of 0.82. Similar analysis using the eight NMR
derived metabolites provided 82% sensitivity and 88% specificity
with an AUROC of 0.86. However, when the metabolite data were
analyzed combining the 12 LC-MS and the 8 NMR detected
metabolites, the model provided much superior performance with
both sensitivity and specificity of 91%, and an AUROC of 0.95.
To evaluate the BE and HGD samples, the same PLS-DA
model was applied, and the result is also shown in Figure 1 (at the
right). BE samples gave a mixed result, and no confident
conclusion could be made because of the small number of
samples. However, most of the HGD samples were predicted as
EAC in this case. The PLS-DA model based on NMR detected
metabolites, and the model based on combining LC-MS and
NMR detected metabolites both showed that 7 out of 9 HGD
patients were indicated as being similar to EAC samples.
Comparing metabolic profiles of EAC and high-risk
patients
The data for high-risk patients (BE and HGD patients) were
combined for the analysis because of their small sample numbers.
Figure 1. Performance comparison of metabolic profiles between EAC patients and healthy controls. (A) Left, result of the PLS-DA
model using 12 metabolite markers from LC-MS analyses; middle, ROC curve using the cross-validated predicted class values (AUROC=0.82); right,
PLS-DA prediction for the BE and HGD samples from the LC-MS model comparing EAC and healthy controls. (B) Same as (A) except using 8 metabolite
markers from NMR analyses, (AUROC=0.86); (C) Same as (A) except using the combination of LC-MS and NMR detected metabolite markers,
(AUROC=0.95).
doi:10.1371/journal.pone.0030181.g001
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detected metabolites varied significantly between EAC and the
high-risk patients, which along with the p-values and fold changes
are shown in Table 1.
PLS-DA models were then built using the LC-MS and NMR
derived metabolite signals, separately and in combination, to test
the classification accuracy for the two patient groups, and the
results are shown in Figure 2. The LC-MS derived metabolites
provided sensitivity and specificity of 83% and 80%, respectively,
with an AUROC of 0.87, and NMR derived metabolites provided
both sensitivity and specificity of 77% with an AUROC of 0.72.
When the data were analyzed combining the LC-MS and NMR
derived metabolites, a sensitivity and specificity of 67% and 97%
were obtained, respectively, with an AUROC of 0.82. Here,
although the performance of the model from the combined data
was slightly better than that from NMR data alone, the model
derived from the LC-MS detected metabolites showed the best
performance. When testing the controls using the same PLS-DA
models derived from the LC-MS detected, NMR detected and
combined metabolites, 22, 12 and 22 of 34 controls were above the
cut-off value, respectively, and were therefore classified as not
being similar to EAC patients.
Comparing metabolic profiles of healthy controls and
high-risk patients
Only one metabolite, pyroglutamic acid, detected by LC-MS,
and three NMR detected metabolites, proline, lactic acid and an
unknown metabolite, differed significantly (p,0.05) between high-
risk patients from healthy controls (Table 1). In addition, a peak
arising from N-acetylated protein in the NMR spectra showed a
significant difference between the two groups. While the levels of
pyroglutamic acid, proline and lactic acid were higher in the high-
risk group, the others were lower.
The LC-MS and NMR data for the high-risk individuals and
healthy controls were compared using PLS-DA analysis (Figure
S2). The lone distinguishing metabolite detected by LC-MS,
pyroglutamic acid, had a sensitivity and specificity of 74% and
75%, respectively, with an AUROC of 0.76. A PLS-DA model
based on the NMR detected metabolites provided a sensitivity and
specificity of 68% and 92%, respectively, with an AUROC of
Figure 2. Performance comparison of metabolic profiles between EAC patients and those with high-risk esophageal diseases (BE
and HGD). (A) Left, result of the PLS-DA model using 7 metabolite markers from LC-MS analyses; middle, ROC curve using the cross-validated
predicted class values (AUROC=0.87); right, PLS-DA prediction for the healthy controls using the model developed using LC-MS metabolites
comparing EAC and high-risk patients. (B) Same as (A) except using the 8 metabolite markers from NMR analyses, (AUROC=0.72). (C) Same as (A)
except using the combination of LC-MS and NMR detected metabolite markers, (AUROC=0.82).
doi:10.1371/journal.pone.0030181.g002
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methods provided results similar to that for NMR alone. However,
all the models failed to give a clear prediction of the EAC patients
using only the high risk and healthy cohorts, indicating that (not
unexpectedly) EAC patient samples are needed to build a
successful detection model.
Trending markers
Levels of the metabolites between the three groups, EAC, BE &
HGD, and healthy controls were compared using box-and-whisker
plots. Interestingly, the average levels for 12 of the metabolites,
including lactic acid, valine, leucine/isoleucine, methionine,
tyrosine, tryptophan, myristic acid, linoleic acid, b-hydroxybuty-
rate, lysine, glutamine and citrate progressively changed with the
average levels for BE and HGD patients falling in between the
levels for healthy controls and EAC (Figure 3). While the levels for
lactic acid, 3-hydroxybutyrate, lysine, glutamine and citrate
increased, the levels for valine, leucine/isoleucine, methionine,
tyrosine, tryptophan, myristic acid and linoleic acid decreased
progressively.
Using these 12 markers, PLS-DA models were again built using
LC-MS and NMR separately and in combination, to test the
classification accuracy for each of the two group comparisons
(Figure 4). Figure 4A shows the PLS-DA model for EAC v. the
healthy controls and predicts values for the high-risk patients. The
model provided a sensitivity and specificity of 89% and 90%,
respectively, with an AUROC of 0.92, although the predictive test
for BE and HGD did not improve over that using the previous
PLS-DA model (Figure 1B and C). Figure 4B shows the PLS-DA
model comparing EAC and the high-risk patient group, resulting
in a sensitivity, specificity and AUROC of 76% 70% and 0.78,
respectively. In this case an improvement in the predictive testing
of the control subjects was obtained, with 30 out of 34 controls
appearing above the cut-off line (non-EAC like). However, these
12 markers could not be used to generate a clear classification
between healthy controls and at risk patients using PLS-DA,
therefore it is not possible to use such a model to predict EAC
(data not shown).
Discussion
This study is focused on identifying distinguishing metabolites
for the establishment of improved clinical biomarkers for EAC
detection, the development of a more robust classification model,
and insights into the altered metabolic pathways in EAC.
The differentiating metabolites derived from the individual LC-
MS and NMR analyses showed distinct differences in a number of
Figure 3. Box-and-whisker plots illustrating progressive changes of the metabolite levels in high-risk patients (BE and HGD) and
esophageal adenocarcinoma (EAC) patients relative to healthy controls. Horizontal line in the middle portion of the box, median; bottom
and top boundaries of boxes, lower and upper quartile; whiskers, 5th and 95th percentiles; open circles, outliers. The first eight markers were
detected by LC-MS, and the remaining four were detected by NMR.
doi:10.1371/journal.pone.0030181.g003
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classification accuracy. However, the combination of metabolic
profiles from the two methods enabled access to an increased
number of distinguishing metabolites. The predictive power of the
model derived from the combination of MS and NMR methods
performed better in both sensitivity and specificity when compared
with the results from the individual analytical methods. The
complementary nature of the combined metabolic pool derived
from the two methods contributed to this improvement of the
model. In fact, all of the LC-MS detected metabolite marker
candidates except lactic acid are different from those detected by
NMR. It should, however, be stressed that while the improvement
in classification was very clear for distinguishing EAC and
controls, when the two analytical methods were combined the
improved performance for discriminating high risk (BE and HGD)
patients versus EAC was less noticeable and only in the high
specificity region (Figures 1 and 2). This effect is likely due to the
small number of high risk patients and possibly to variation of
metabolic alterations to a greater degree from one patient to
another, both of which can make model prediction more
challenging.
Comparison of the individual metabolites and the statistical
models developed using the differentiating metabolites in the three
groups showed that metabolic profiles of the BE and HGD
patients were different from both EAC patients and healthy
controls. Progressive changes in the levels of 12 metabolites
derived from LC-MS and NMR methods indicate the potential
utility for identifying BE and HGD patients who may develop
EAC (Figure 3). This is particularly important since BE and HGD
are major risk factors for the development of EAC. Identification
of metabolites in these patients, which are potentially predictive of
the development of EAC is particularly important for the
management of at risk patients.
Identification of the metabolic pathways associated with specific
metabolites displaying altered levels can improve the understand-
ing of the biology and pathology in the trajectory from normal to
esophageal disease and ultimately cancer. Previously, we showed a
simplified pathway map based on the metabolite markers
identified by NMR and compared the results with other type of
cancers [27]. Building upon this model, Figure 5 shows a more
detailed pathway map associated with metabolite markers
identified using both MS and NMR methods. Altered pathways
include changes in amino acid metabolism, biosynthesis and
degradation (glutamine, lysine, carnitine, valine, leucine/isoleu-
cine, methionine, tryptophan, 5-hydroxytrytophan, and tyrosine),
glycolysis (lactate and glucose), ketone bodies synthesis and
degradation (b-hydroxybutyate), tricarboxylic acid (TCA) cycle
(citrate) and fatty acid metabolism (linoleic acid, linolenic acid and
myristic acid).
Energy metabolism and the TCA cycle dominate the altered
biochemistry of EAC. Accumulation of lactate and glucose, which
is common in many cancers mirrors the demand for higher energy
in tumor malignancy [32]. The increase of carnitine in the EAC
patients indicates increased activity of carnitine, lysine and
glutamine biosynthesis connected with the TCA cycle via lactate
accumulation, again in response to the higher energy demand of
the tumor. Many serum amino acids, including valine, leucine/
isoleucine, tyrosine, methionine, tryptophan and 5-hydroxytryto-
phan, were down-regulated in EAC patients compared with
healthy controls, which indicates an increased demand for and
overutilization of amino acids in the tumor tissue, as further
evidenced by other reports on the cancer [25,26] as well as other
malignant tumors [33,34]. Fatty acid metabolism is also altered in
the cancer patient sera, as seen by the reduced levels of a number
of fatty acids, and which is also in accordance with findings in
serum from other cancers such as colorectal cancer [35].
We also noticed that valine and tyrosine were decreased in the
sera of patients in the current study, but increased in the tissue of
EAC patients [25]. The intriguing differential regulation of certain
metabolites in biofluids versus tissue samples for the same disease
Figure 4. PLS-DA models comparing two patient groups, their coresponding ROC curves, and the prediction of the models for the
other (third) patient group using the 12 trending markers of Figure 3. (A) Performance comparison of metabolic profiles between EAC
patients and healthy controls, AUROC=0.92. (B) Performance comparison of metabolic profiles between EAC and BE/HGD patients, AUROC=0.78.
doi:10.1371/journal.pone.0030181.g004
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well. For example, while histidine increased in colorectal cancer
patient tissue [36], it was depleted in urine [37]. Thus, to examine
the intimate correlation of serum, urine and tissue metabolism as a
whole, similar methodologies should be utilized to identify the
metabolic alterations and pathways of the same study subjects in a
broader range of sample types [38]. It would also be of interest to
provide a more dynamic metabolic picture by determining
metabolic fluxes or other changes in the metabolic pathways that
may be altered in the presence of the disease [39,40,41].
In conclusion, we have shown that the metabolic profiling of serum
using a combination of LC-MS and
1H NMR, along with multivariate
statistical methods allows a detailed picture of metabolic changes in
EAC and patients with high cancer risk (BE and HGD), compared
with healthy controls. These patient groups can be distinguished from
one another with good accuracy. Performance of the combination the
two analytical methods is particularly striking for distinguishing EAC
and controls. As the two analytical largely detect different metabolites,
their combined use for global metabolic profiling is advantageous.
However, the improved performance for discriminating high risk (BE
and HGD) patients versus EAC is not large, and only noticeable for
the high specificity region of the ROC curve. This result is likely due to
the small number of patients and the relatively poor performance of
the NMR detected markers in the challenging task of distinguishing at
risk patient from those with EAC. Progressive changes in a number of
metabolites between the three groups are particularly noteworthy
since these metabolites, which vary gradually from controls to BE and
HGD and EAC, may be potentially useful biomarkers to detect
esophageal cancer early.
Supporting Information
Figure S1 Box-and-whisker plots illustrating differenc-
es between EAC patients, high-risk patients (BE and
HGD) and healthy controls for the 12 markers detected
from LC-MS. Y-axis of each plot indicates the signal intensities.
(TIF)
Figure S2 Comparison results for metabolic profiles
from healthy controls with high-risk, BE and HGD,
patients. (A) Left, result of the PLS-DA model for the one
metabolite from LC-MS; middle, ROC curve for the cross-
validated predicted class values (AUROC=0.76); right, PLS-DA
prediction for the EAC samples using the same metabolite and
cutoff. (B) Left, result of the PLS-DA model comparing healthy
normals and high risk patients (BE & HDG) for the 4 markers
detected by NMR; middle, ROC curve for the cross-validated
predicted class values (AUROC=0.80); right, PLS-DA prediction
for the EAC samples using the model developed using NMR
markers for high-risk indivduals and healthy controls. (C) Same as
(B) except using the combination of 5 markers from LC-MS and
NMR (AUROC=0.80).
(TIF)
Figure 5. Altered metabolism pathways for the most relevant metabolic differences between patients with EAC and control
subjects. Blue boxes indicate metabolites that are up-regulated in EAC patient sera, while red boxes indicate metabolites that are down-regulated.
Metabolites in bold showed mean levels that changed progressively from control to high-risk esophagus diseases (BE and HGD) and ultimately EAC.
doi:10.1371/journal.pone.0030181.g005
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